An FDA mistake signals likely approval for Vivek Ramaswamy’s first therapy for children...

[cafead]

via The FDA on Thursday accidentally published a notice announcing the award of a priority review voucher to rare disease drug developer Enzyvant for its new regenerative therapy for the treatment of pediatric patients with congenital athymia.

The only problem? The treatment still hasn’t won FDA approval.

article source